vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and JOINT Corp (JYNT). Click either name above to swap in a different company.

JOINT Corp is the larger business by last-quarter revenue ($15.2M vs $14.7M, roughly 1.0× IRIDEX CORP). On growth, JOINT Corp posted the faster year-over-year revenue change (3.1% vs -69.7%). Over the past eight quarters, IRIDEX CORP's revenue compounded faster (11.9% CAGR vs -28.6%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.

IRIX vs JYNT — Head-to-Head

Bigger by revenue
JYNT
JYNT
1.0× larger
JYNT
$15.2M
$14.7M
IRIX
Growing faster (revenue YoY)
JYNT
JYNT
+72.8% gap
JYNT
3.1%
-69.7%
IRIX
Faster 2-yr revenue CAGR
IRIX
IRIX
Annualised
IRIX
11.9%
-28.6%
JYNT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRIX
IRIX
JYNT
JYNT
Revenue
$14.7M
$15.2M
Net Profit
$991.1K
Gross Margin
37.2%
81.4%
Operating Margin
4.9%
Net Margin
6.5%
Revenue YoY
-69.7%
3.1%
Net Profit YoY
5510.5%
EPS (diluted)
$0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
JYNT
JYNT
Q4 25
$14.7M
$15.2M
Q3 25
$12.5M
$13.4M
Q2 25
$13.6M
$13.3M
Q1 25
$11.9M
$13.1M
Q4 24
$12.7M
$14.7M
Q3 24
$11.6M
$30.2M
Q2 24
$12.6M
$30.3M
Q1 24
$11.8M
$29.7M
Net Profit
IRIX
IRIX
JYNT
JYNT
Q4 25
$991.1K
Q3 25
$-1.6M
$855.0K
Q2 25
$-994.0K
$93.4K
Q1 25
$-1.7M
$967.8K
Q4 24
$-834.0K
$17.7K
Q3 24
$-1.9M
$-3.2M
Q2 24
$-2.7M
$-3.6M
Q1 24
$-3.5M
$947.0K
Gross Margin
IRIX
IRIX
JYNT
JYNT
Q4 25
37.2%
81.4%
Q3 25
32.1%
80.1%
Q2 25
34.5%
79.1%
Q1 25
42.5%
77.3%
Q4 24
44.0%
78.4%
Q3 24
37.3%
90.7%
Q2 24
40.7%
90.7%
Q1 24
37.9%
90.9%
Operating Margin
IRIX
IRIX
JYNT
JYNT
Q4 25
4.9%
Q3 25
-11.3%
1.2%
Q2 25
-6.9%
-8.6%
Q1 25
-1.7%
-5.2%
Q4 24
-3.9%
5.5%
Q3 24
-16.1%
-1.6%
Q2 24
-20.9%
-5.9%
Q1 24
-28.0%
-1.4%
Net Margin
IRIX
IRIX
JYNT
JYNT
Q4 25
6.5%
Q3 25
-12.6%
6.4%
Q2 25
-7.3%
0.7%
Q1 25
-14.2%
7.4%
Q4 24
-6.6%
0.1%
Q3 24
-16.7%
-10.5%
Q2 24
-21.2%
-11.9%
Q1 24
-29.5%
3.2%
EPS (diluted)
IRIX
IRIX
JYNT
JYNT
Q4 25
$0.06
Q3 25
$-0.09
$0.06
Q2 25
$-0.06
$0.01
Q1 25
$-0.10
$0.06
Q4 24
$-0.05
$0.01
Q3 24
$-0.12
$-0.21
Q2 24
$-0.16
$-0.24
Q1 24
$-0.21
$0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
JYNT
JYNT
Cash + ST InvestmentsLiquidity on hand
$6.0M
$23.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$15.1M
Total Assets
$29.2M
$61.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
JYNT
JYNT
Q4 25
$6.0M
$23.6M
Q3 25
$5.6M
$29.7M
Q2 25
$6.8M
$29.8M
Q1 25
$7.2M
$21.9M
Q4 24
$2.4M
$25.1M
Q3 24
$3.9M
$20.7M
Q2 24
$4.1M
$17.5M
Q1 24
$5.4M
$18.7M
Total Debt
IRIX
IRIX
JYNT
JYNT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
IRIX
IRIX
JYNT
JYNT
Q4 25
$15.1M
Q3 25
$4.7M
$22.7M
Q2 25
$6.1M
$23.2M
Q1 25
$852.0K
$22.8M
Q4 24
$2.1M
$20.7M
Q3 24
$2.6M
$20.5M
Q2 24
$4.2M
$23.2M
Q1 24
$6.5M
$26.2M
Total Assets
IRIX
IRIX
JYNT
JYNT
Q4 25
$29.2M
$61.0M
Q3 25
$28.4M
$69.4M
Q2 25
$31.6M
$73.2M
Q1 25
$34.2M
$80.1M
Q4 24
$29.1M
$83.2M
Q3 24
$30.2M
$79.6M
Q2 24
$31.2M
$82.4M
Q1 24
$34.1M
$85.7M
Debt / Equity
IRIX
IRIX
JYNT
JYNT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
JYNT
JYNT
Operating Cash FlowLast quarter
$1.8M
Free Cash FlowOCF − Capex
$334.7K
FCF MarginFCF / Revenue
2.2%
Capex IntensityCapex / Revenue
9.9%
Cash ConversionOCF / Net Profit
1.86×
TTM Free Cash FlowTrailing 4 quarters
$-1.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
JYNT
JYNT
Q4 25
$1.8M
Q3 25
$-1.2M
$1.8M
Q2 25
$-397.0K
$868.6K
Q1 25
$-1.1M
$-3.7M
Q4 24
$-1.2M
$9.4M
Q3 24
$-3.1M
$3.4M
Q2 24
$-1.3M
$-973.5K
Q1 24
$-1.6M
$2.8M
Free Cash Flow
IRIX
IRIX
JYNT
JYNT
Q4 25
$334.7K
Q3 25
$-1.2M
$1.5M
Q2 25
$-410.0K
$363.6K
Q1 25
$-1.2M
$-4.0M
Q4 24
$-1.2M
$8.2M
Q3 24
$-3.1M
$3.2M
Q2 24
$-1.2M
Q1 24
$-1.7M
$2.4M
FCF Margin
IRIX
IRIX
JYNT
JYNT
Q4 25
2.2%
Q3 25
-9.4%
10.9%
Q2 25
-3.0%
2.7%
Q1 25
-9.8%
-30.8%
Q4 24
-9.8%
55.9%
Q3 24
-26.5%
10.6%
Q2 24
-4.1%
Q1 24
-14.0%
8.1%
Capex Intensity
IRIX
IRIX
JYNT
JYNT
Q4 25
9.9%
Q3 25
0.1%
2.4%
Q2 25
0.1%
3.8%
Q1 25
0.1%
2.5%
Q4 24
0.1%
8.1%
Q3 24
0.0%
0.8%
Q2 24
0.0%
0.9%
Q1 24
0.0%
1.3%
Cash Conversion
IRIX
IRIX
JYNT
JYNT
Q4 25
1.86×
Q3 25
2.07×
Q2 25
9.30×
Q1 25
-3.82×
Q4 24
532.98×
Q3 24
Q2 24
Q1 24
2.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IRIX
IRIX

Segment breakdown not available.

JYNT
JYNT

Transferred At Point In Time$12.8M84%
Transferred Over Time$2.4M16%

Related Comparisons